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A negative impact of anemia on the outcome 
of cancer patients treated with chemoradiotherapy 
is well known, with a reduction of treatment efficacy 
by anemia-induced tumor hypoxia being a popular 
explanation [1, 2]. However, a low concentration 
of pre-treatment hemoglobin had been related to poor 
outcome also in patients treated surgically [3–5], 
even in cases when prognosis had traditionally been 
favorable [6]. Therefore, it has been hypothesized 
that the presence of anemia might reflect a more ag-
gressive tumor phenotype [6], related among others 
to the up-regulation of angiogenic factors due to the 
anemia-induced tumor hypoxia [7, 8]. Yet, whether 
or how anemia is associated with tumor hypoxia re-
mains debatable [9]. Moreover, data on anemia impact 
on up-regulation of angiogenic factors are contradic-
tory as well [10–12]. Furthermore, some of the clinical 
trials with human recombinant erythropoietin have 
worsened patients’ outcome despite the improvement 
of hemoglobin concentration [6, 9]. In the light of exis-
ting controversies, the detailed studies on mecha-
nisms underlying the advocated association of anemia 
with tumor aggressiveness mediated by tumor hypoxia 
and subsequent angiogenesis should precede the 
implementation of new treatment strategies.
Studies on anemia in esophagogastric cancers have 
been focused on its adverse impact on a quali ty of life, 
duration of survival and treatment response [13–16]. 
Our objectives were the evaluation of relation between 
pre-treatment anemia and various manifestations 
of disease aggressiveness and determination whether 
the presence of cancer-related anemia is associated 
with up-regulation of circulating mediators of angio-
genesis: vascular endothelial growth factors A and 
C (VEGF-A and VEGF-C), interleukin 8 (IL-8) and mid-
kine, the latter being a relatively new angiogenic factor 
[17]. All these cytokines exhibit both angiogenic and 
proinflammatory properties and have been connected 
to aggressiveness of esophagogastric cancers [18–21]. 
Therefore, if causative relationship between anemia-
hypoxia-angiogenesis is valid, their adverse relation 
to hemoglobin concentration might be expected.
METHODS
Patients. The Medical Ethics Committee of our 
University approved the study protocol.We examined 
111 patients of Gastrointestinal and General Surgery 
Department of our University with histopathologically 
confirmed esophageal squamous cell carcinomas 
(SCC; n = 72) or esophagogastric adenocarcinomas 
(ADC; n = 39), staged clinically according to TNM sys-
tem [22]. There were: stage II — 20 cases, stage III — 
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33 cases, stage IV — 58 cases; 20 females, 91 males; 
median age 59 (range: 35–85).
Data on patients’ hemoglobin level, platelet (PLT), 
leukocyte (WBC), neutrophil (NEU) and total lympho-
cyte (TLC) counts, were collected retrospectively from 
case histories on condition that blood samples for 
hematological analysis and angiogenic factors deter-
mination were obtained simultaneously and preceded 
any treatment. Data on patients’ body mass index 
(BMI) and weight loss due to the disease were also 
collected. Reported weight loss of > 5% of body weight 
per three months was considered as substantial.
Anemia was defined in terms of hemoglobin 
concentration (females: Hb < 12 g/dL; males: 
Hb < 13 g/dL), verified by hematocrit level.
Analytical methods. Levels of angiogenic factors 
were measured in sera obtained from blood clotted for 
15 min at room temperature and centrifuged (15 min, 
3000 rpm). VEGF-A and VEGF-C levels were assayed 
according to the manufacturer instructions by immu-
noenzymatic tests (IBL-Hamburg, Germany). Il-8 was 
determined with PeliKine Compact human Il-8 ELISA 
kit (Sanquin, Holland). Midkine was determined 
by double-antibody sandwich indirect ELISA accord-
ing to the procedure previously described [23]. All 
measurements were duplicated.
Statistical analysis. Hemoglobin concentrations are 
presented as mean with 95% confidence interval (CI). 
Analysis of differences in mean hemoglobin levels was 
conducted with two-tailed t-test for independent samples 
or one-way ANOVA. Comparisons of anemia frequency 
were conducted with Chi-square test. Correlation was 
analyzed with Pearson moment-product correlation test, 
Spearman correlation rank test or Kendall tau test with 
respect to variable distribution and type (categorical/con-
tinuous). Distribution normality of raw or log-transformed 
data was tested with D’Agostino-Pearson test.
Receiver Operating Characteristics (ROC) analysis 
for determination of optimal hemoglobin cut-off value 
and likelihood ratios calculation (positive: LR+; nega-
tive: LR–) was performed.
A stepwise method of multiple and logistic regression 
was employed (entrance condition: p < 0.05, removal 
condition: p > 0.1). Multiple regression was applied for 
prediction of continuous variables (hemoglobin concen-
tration) and logistic regression for dichotomous variables 
(anemia and cancer dissemination). Number of entered 
independent variables was limited to preserve 1 : 10 ratio 
with sample number. Categorical variables were dichoto-
mized by grouping T2–T3 cancers vs. T4 and stages I–III 
vs IV. p values ≤ 0.05 were considered significant.
RESULTS
The prevalence of anemia in our patients was 64%; 
mean Hb level — 11.9 g/dL (CI: 11.5–12.3). In non-
anemic patients mean hemoglobin concentration was 
14 g/dL (CI: 13.6–14.3) and 10.8 mg/dL (CI: 10.4–11.1) 
in anemic patients (p < 0.0001). 48 subjects had mild 
(Hb: 10 to 12–13 g/dL) while 23 moderate/severe 
anemia (Hb < 10 g/dL).
We analyzed the association of anemia prevalence 
or hemoglobin concentration with cancer-related and 
patient-related variables of esophagogastric cancers 
(Table 1). The strength of the relations with included 
biochemical parameters (blood cell counts and serum 
levels of angiogenic factors) was assessed in cor-
relation analysis (Table 2). Additionally, we found that 
when hemoglobin level dropped < 11 g/dL, a tendency 
towards a weak negative correlation with VEGF-A oc-
curred (rho = –0.178, p = 0.289).
Table 1. Relation of anemia and hemoglobin (Hb) concentration 
to clinico-pathological factors in gastroesophageal cancer patients
Clinico-
pathological 
variables
Frequency of anemia 
in respect to cancer clinico-
pathological variables
Relation between Hb level 
and cancer clinico-
pathological variables
Normal Anemia p value
Mean Hb level 
[g/dL] 
(with 95% CI)
p value
Gender:
Female 10 10 0.238Ch 11.5 (10.9–12.2) 0.214t
Male 30 61 12.0 (11.5–12.4)
Tumor histology:
squamous cell 
carcinoma
32 40 0.024Ch 12.5 (12.1–12.8) <0.001t
adenocarcinoma 8 31 10.9 (10.2–11.7)
Regional 
metastasis:
N0 19 15 < 0.001Ch 12.6 (11.9–13.3) 0.003t
N1 13 52 11.3 (10.8–11.8)
Distant 
metastasis:
M0 25 39 0.565Ch 12.0 (11.5–12.5) 0.544t
M1 15 32 11.8 (11.2–12.4)
Cancer 
dissemination:
localized 14 9 0.006Ch 13.0 (12.2–13.9) 0.001t
disseminated 23 61 11.6 (11.1–12.0)
BMI:
> 18.5 21 41 0.477Ch 12.2 (11.6–12.7) 0.382t
< 18.5 12 15 11.8 (11.2–12.4)
Weight loss:
unsubstantial 17 33 0.679Ch 11.9 (11.3–12.5) 0.756t
substantial 20 30 12.0 (11.4–12.6)
Tumor size:
< 5 cm 9 10 0.428Ch 12.4 (11.3–13.5) 0.253t
> 5 cm 30 57 11.8 (11.4–12.2)
Primary tumor 
extension:
T2 8 9 0.192Ch 12.4 (11.2–13.5) 0.549A
T3 16 21 (0.087)ChT 12.0 (11.3–12.6)
T4 16 41 11.8 (11.2–12.3)
Disease stage:
I/II 11 9 0.119Ch 12.6 (11.6–13.7) 0.041A
III 12 21 (0.047)ChT 12.3 (11.6–12.9)
IV 17 41 11.5 (10.9–12.0)
Notes: Hb – hemoglobin concentration; CI – confidence intervals; ChChi-
square test; ChTChi-square test for trend; ttwo-sided t-test for independent 
samples; Aone way ANOVA.
Since our results revealed hemoglobin association 
with cancer metastasis, ROC analysis was performed 
to determine the optimal hemoglobin levels discriminating 
between non-metastasizing and metastasizing cancers. 
The optimal hemoglobin threshold value was 12.1 g/dL for 
disseminated cancers and 12.5 g/dL for cancers metasta-
sizing to lymph nodes. Likelihood ratios were LR+ = 2.85, 
LR– = 0.49 and LR+ = 1.91, LR– = 0.37, respectively.
We conducted multiple regression analysis in order 
to establish which of the cancer or patient-related 
variables and/or biochemical parameters account for 
changes in blood hemoglobin concentration. Similarly, 
logistic regression was applied to determine predic-
tors of anemia. Only those variables, which were found 
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significant in correlation analysis (marked with asterisk 
see in Table 2), were included.
Table 2. Correlation analysis between the presence of anemia or hemoglobin 
concentration and patient-related, cancer-related and biochemical variables 
in esophagogastric cancer patients
Variable
Presence of anemia Hemoglobin level
Correlation coefficient; 
p value
Correlation coefficient; 
p value
Age
Sex
BMI
Weight loss
Histology
Disease stage
Tumor extension (T)
Tumor size
Dissemination
Regional metastasis
Distant metastasis
WBC
TLC
NEU
PLT
VEGF-A
VEGF-C
Il-8
Midkine
rho = 0.194, p = 0.044*
tau = 0.136, p = 0.034*
tau = 0.101, p = 0.160
tau = –0.062, p = 0.356
tau = 0.238, p < 0.001*
tau = 0.166, p = 0.010*
tau = 0.163, p = 0.011*
tau = 0.102, p = 0.121
tau = 0.289, p < 0.0001*
tau = 0.364, p < 0.0001*
tau = 0.074, p = 0.255
rho = –0.007, p = 0.939
rho = –0.411, p < 0.001*
rho = 0.108, p = 0.305
rho = 0,043, p = 0.650
rho = 0.047, p = 0.628
rho = –0.022, p = 0.821
rho = 0.076, p = 0.437
rho = 0.266, p = 0.005*
rho = –0.100, p = 0.293
rho = 0.085, p = 0.373
rho = –0.079, p = 0.461
rho = 0.042, p = 0.679
rho = –0.348, p < 0.001*
rho = –0.218, p = 0.022*
rho = –0.102, p = 0.287
rho = –0.095, p = 0.329
rho = –0.300, p = 0.002*
rho = –0.296, p = 0.003*
rho = –0.052, p = 0.585
rho = 0.063, p = 0.511
rho = 0.419, p < 0.001*
rho = –0.095, p = 0.368
rho = –0.089, p = 0.351
r = 0.052, p = 0.592
rho = 0.096, p = 0.331
r = –0.155, p = 0.113
rho = –0.286, p = 0.003*
Notes: Test application depended on variable distribution and type 
(rho-Spearman, tau-Kendall, r-Pearson); *significant relations.
Tumor histology, TLC and midkine were found 
to exert independent effect on hemoglobin concen-
tration in esophagogastric cancer patients. Resulting 
coefficient of determination (R2) of the model was 
0.338 and multiple correlation coefficient (R) was 
0.581 (p < 0.001). Regression coefficients of individual 
variables are presented in Table 3. We excluded mid-
kine from the model to evaluate the usefulness of this 
parameter. The strength of a new model was similar 
(R2 = 0.321, R = 0.566, p < 0.001), yet midkine was 
replaced by dissemination variable (Table 3).
Table 3. Results of multiple regression analysis (stepwise method) 
with hemoglobin concentration in esophagogastric cancer patients 
as a dependent variable
Entered variables: histology, midkine, TLC, dissemination, stage, regional 
metastasis
Independent variables 
retained in the model
Regression 
Coefficient Standard error p value
Histology
Midkine
TLC
–1.21333
–0.00045
1.07550
0.36857
0.00016
0.27780
0.002
0.007
< 0.001
Entered variables: histology, TLC, dissemination, stage, regional 
metastasis
Dissemination
Histology
TLC
–1.02697
–1.20672
0.97746
0.43865
0.37777
0.28143
0.022
0.002
< 0.001
Note. TLC — total lymphocyte count.
In turn, variables that exert an independent effect 
on anemia presence were midkine, TLC, age and re-
gional metastasis. The significance of overall model fit 
was p < 0.0001 and its accuracy 86%. Odds’ ratios for 
individual variables are presented in Table 4.
In multiple regression model midkine was replaced 
by cancer dissemination without substantial loss 
of model’s strength, suggesting that hemoglobin as-
sociation with cancer dissemination can be mediated 
by midkine. Hence, we performed logistic regression 
analysis in search for variables, which exert an inde-
pendent effect on cancer dissemination and found that 
midkine alone was an independent variable (Table 5).
Table 4. Results of logistic regression analysis (stepwise method) 
with the presence of anemia in esophagogastric cancer patients 
as a dependent variable
Entered variables: midkine, TLC, age, regional metastasis, dissemination, 
histology, sex, stage, tumor extension
Retained 
variable
Regression 
coefficient
Standard 
error p value ODDs ratios (95% CI)
Midkine
TLC
Age
Regional 
metastasis
0.0011
-1.4059
0.0770
1.4746
0.0004
0.5265
0.0347
0.6829
0.0097
0.0076
0.0264
0.0308
1.0011 (1.0003–1.0019)
0.2452 (0.0874–0.6880)
1.0800 (1.0091–1.1560)
4.3692 
(1.1459–16.6595)
Notes: TLC — total lymphocyte count; CI — confidence interval.
Table 5. Results of logistic regression analysis (stepwise method) with 
the presence of cancer dissemination in esophagogastric cancer patients 
as a dependent variable
Entered variables: stage, tumor extension, histology, hemoglobin, PLT, 
WBC, TLC, VEGF-A, Il-8, midkine
Retained 
variable
Regression 
coefficient
Standard 
error p value ODDs ratios (95% CI)
Midkine 0.0015 0.0005 p < 0.001 1.001 (1.000–1.002)
Notes: PLT — platelet count, WBC — leukocyte count; TLC — total lymphocyte 
count.
DISCUSSION
We found that anemia prevalence and hemoglobin 
concentration were related to cancer dissemination 
in esophagogastric cancers. Similarly, Knight et al. [24] 
summarized that the prevalence of anemia associated 
with other cancer types varied not only with tumor type 
but also with metastasis presence. Our finding that 
stronger association can be found with regional rather 
than distant metastasis corroborates well the results 
of Rades et al. [14, 16], who reported that anemia in pa-
tients with esophageal cancer was one of the strongest 
independent predictors of locoregional recurrence after 
radiotherapy but not of shortened metastasis free sur-
vival. The same authors demonstrated that locoregional 
recurrence rates were three times higher in anemic 
than non-anemic patients and that locoregional control 
of esophageal cancer could be improved by the admi-
nistration of epoetin-alpha [15, 16].
Some investigators argue that the impact of anemia 
on prognosis results from anemia relation to tumor vo-
lume [25]. Indeed, anemia prevalence has been higher 
in T4 prostate cancer than T0–T3 cancers [24]. But 
Rades et al. [13, 14] showed that in esophageal cancer 
both hemoglobin concentration and tumor length were 
independent prognostic variables. Hemoglobin has 
been associated with locoregional control while tumor 
length with metastasis free survival [13, 16]. Other 
authors [26] reported that in multivariate analysis only 
hemoglobin concentration was an independent sur-
vival predictor in esophageal carcinoma. We, in turn, 
observed that hemoglobin concentration was related 
neither to tumor size nor to the extension of primary 
tumor, although frequency of anemia tended to depend 
on tumor extension with a weak, yet significant, correla-
tion between variables. However, tumor extension was 
not selected as variable exerting independent effect 
on hemoglobin level or anemia presence.
As could be expected, a large number of our pa-
tients was anemic and anemia presence was related 
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to age. The prevalence of anemia was in agreement 
with the results summarized by Varlotto et al. [9] and 
with the data from The European Cancer Anemia 
Survey (ECAS) [27]. Although only 31% of patients 
with gastrointestinal cancers were found to be anemic 
at the beginning of ECAS, the number was doubled 
during the survey. High anemia prevalence can be ex-
plained by its tendency to depend on disease stage. 
On one hand we found a positive correlation between 
disease stage and both anemia presence and hemo-
globin level. On the other hand, which is characteristic 
for esophagogastric cancers, most of our patients 
were diagnosed with advanced, non-operable tumors 
and submitted to palliative treatment.
Results of our studies support the hypothesis that 
anemia is related to tumor aggressiveness, espe-
cially to lymph node involvement. Assuming that a link 
between hemoglobin level and tumor oxygenation 
is valid, this result corroborates the finding that poorly 
oxygenated tumors had larger lymphatic-vascular 
space invasion as compared to better oxygenated 
ones [9]. Angiogenesis is a condition of success-
ful dissemination of transformed cells. Since many 
angiogenic factors have been implicated in regional 
metastasis [28], we evaluated whether they may me-
diate the anemia association with cancer dissemina-
tion. And indeed, a significant relation to hemoglobin 
concentration and anemia presence was observed 
in case of midkine, while a tendency towards weak 
adverse association of hemoglobin level with Il-8 and 
VEGF-A was also found. Yet, the latter relation mani-
fested itself when the hemoglobin dropped below 
11 g/dL. Moreover, midkine was found to exert an inde-
pendent effect on both hemoglobin concentration and 
anemia presence. In our previous studies we observed 
that midkine levels were elevated in cachectic patients 
with esophagogastric cancer [29] and mechanisms 
of both cancer-related cachexia and anemia seem 
to share a lot of similarities [30]. Association of anemia 
with VEGF-A, a key regulatory factor of angiogenesis, 
has already been studied in selected cancers but 
yielded contradictory results. Dunst et al. [10, 31, 32] 
consequently reported a significant relation between 
hemoglobin concentration and circulating VEGF-A, 
but has not been confirmed by other authors [11, 12]. 
We also failed to corroborate such correlation.
The cause-effect relationship between anemia, 
tumor hypoxia, angiogenic factors’ up-regulation, 
promotion and facilitation of cancer cells dissemina-
tion appears to be an attractive explanation of anemia 
association with tumor aggressiveness. Our results 
seem to support individual elements of this sequence 
since at least some of the angiogenic factors are re-
lated to anemia presence and to cancer metastasis. 
Moreover, midkine was directly replaced by cancer 
dissemination in multiple regression analysis without 
significant lost to the model’s strength. At the same 
time, however, our results may be interpreted as in-
direct evidence supporting the hypothesis that other 
factors, additional to tumor hypoxia, mediate anemia 
impact on tumor aggressive behavior. We found that 
even a mild anemia was related to tumor aggressive-
ness, which is in agreement with recent understanding 
of anemia impact on cancer patients’ outcome [33]. 
ROC analysis revealed that hemoglobin concentration 
below 12.1 g/dL was almost three times more likely 
to be seen in patients with disseminated than locali-
zed cancers, while it was almost twice more probable 
to find hemoglobin < 12.5 g/dL in patients with regional 
metastasis than in those without. In the meanwhile, 
markedly lower hemoglobin levels were reported 
to impair significantly tumor oxygenation [6, 25, 34, 
35]. In accordance with it, we observed that only in pa-
tients with moderate/severe anemia VEGF-A tended 
to adversely correlate with hemoglobin concentration. 
Therefore, it can be speculated that apart from tumor 
oxygenation status there are other mechanisms that 
can trigger oversecretion of proinflammatory and 
angiogenic cytokines, which may account for their 
up-regulation in mild anemia. The existence of more 
complex mechanisms behind anemia association with 
tumor aggressiveness seems to be advocated by the 
results of most of studies comparing anemia and tumor 
hypoxia as predictors of cancer patients’ outcome, 
where the level of pre-treatment hemoglobin was more 
important prognostic determinant than oxygenation 
status of tumor tissue [9].
Nutrient deprivation might be a good candidate 
and oversecretion of some angiogenesis mediators 
due to nutrient deprivation has been found [36]. We, 
in turn, observed that both hemoglobin concentration 
and anemia presence were strongly associated with to-
tal lymphocyte count, a surrogate marker of nutritional 
status. Moreover, other markers of malnutrition have 
been reported to correlate with hemoglobin on one 
hand [30] and patients’ survival on the other [3].
Additionally, contrary to lung cancer [37], we ob-
served that tumor histology was related to hemoglobin 
concentration and anemia presence. However, the 
proportion of metastasizing cancers was higher in ade-
nocarcinoma than squamous cell carcinoma group, 
what may account for the higher frequency of anemia 
in the former. Yet, since histology was found to exert 
an independent effect on hemoglobin concentration, 
further elucidation of this issue is required.
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